[Epidemiology and economics of chemotherapy combinations in the treatment of advanced breast cancer].
125 oncologists, taken at random from a French professional list, followed up a cohort of 836 patients suffering from advanced breast cancer and treated by chemotherapy. The following data were collected prospectively: socio-demographics of patients and practitioners, disease history, characteristics of one chemotherapy cycle (type, utility and cost). A total of 89 chemotherapy combinations were described during the first-line treatment, independently of doses, eight combinations representing 70 per cent of all the prescriptions. No statistically significant differences were found when comparing the utility of the most often used combinations. Chemotherapy was the main cost driver of administration, rising to 90 per cent of the total cost when using taxans, followed by CSF. The cost price of taxan administration was twice to three times that of FEC or vinorelbine associations. These differences were poorly taken into account by the French budget allocation system as based on Diagnosis Related Groups.
Martin
J P
JP
Clinique Saint-Jean, Lyon, France.
Diéras
V
V
Berdeaux
G
G
D000972:Antineoplastic Agents, Phytogenic / Q000191:economics / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000191:economics / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000191:economics / Q000453:epidemiology; D016527:Drug Costs; D005260:Female; D005602:France / Q000453:epidemiology; D006760:Hospitalization / Q000191:economics; D006801:Humans; D007902:Length of Stay; D008875:Middle Aged; D017239:Paclitaxel / Q000191:economics / Q000627:therapeutic use; D011446:Prospective Studies; D012959:Socioeconomic Factors
D000972:Antineoplastic Agents, Phytogenic; D017239:Paclitaxel
Epidémiologie et économie des associations de chimiothérapies dans le traitement du cancer du sein métastasé.